TOPIVERT
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
TOPIVERT
Industry:
Angel Investment Biotechnology Health Care Management Information Systems
Founded:
2011-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.topivert.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
19.9 M USD
Technology used in webpage:
Google Analytics Google Universal Analytics GoDaddy DNS ASP.NET IIS Pound Sterling IIS 8 Parallels Plesk Panel Plesk Classic ASP
Current Advisors List
Current Employees Featured
Founder
Investors List
SV Health Investors
SV Health Investors investment in Series A - TopiVert
Neomed Management
Neomed Management investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Official Site Inspections
http://www.topivert.com Semrush global rank: 5.39 M Semrush visits lastest month: 1.56 K
- Host name: ec2-13-223-25-84.compute-1.amazonaws.com
- IP address: 13.223.25.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TopiVert"
TopiVert - Crunchbase Company Profile & Funding
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines …See details»
Topivert Pharma Limited Management Team | Org Chart
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic …See details»
Topivert Pharma Limited - LinkedIn
Topivert Pharma Limited | 446 followers on LinkedIn. TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic ...See details»
TopiVert 2025 Company Profile: Valuation, Funding & Investors
TopiVert General Information Description. Developer of medical inhibition technologies designed to treat chronic inflammatory diseases of the gastrointestinal tract and the eyes. The …See details»
Topivert Pharma Limited - Company Profile & Staff Directory
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic …See details»
TopiVert Company Profile - Office Locations, Competitors ... - Craft
TopiVert has adopted a semi-virtual business model, using a combination of in-house expertise and a strong network of advisers and service providers to expedite our programmes and …See details»
TopiVert - VentureRadar
Topivert Ltd is a spin out company focussing on the development of small molecule drugs to treat severe inflammation of the gastrointestinal (GI) tract and eye. The company is based in the …See details»
TopiVert: Revenue, Worth, Valuation & Competitors 2024
About TopiVert. TopiVert is a Pharmaceuticals related company founded in 2011 and based in Stevenage with an estimated revenue of $7.8M, and 39 employees. It has 10 competitors …See details»
Topivert - 2025 Company Profile, Funding & Competitors - Tracxn
May 5, 2025 TopiVert is a clinical-stage company focussed on developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases of the gastrointestinal tract …See details»
TopiVert Corporate Headquarters, Office Locations and Addresses
TopiVert Headquarters and Office Locations. Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit. Button CTA. TopiVert is headquartered in London, 52 Princes …See details»
Topivert Ltd. - BioCentury Company Profiles - BCIQ
Jan 10, 2023 Topivert Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
About Topivert - Health/Medical company in United Kingdom - F6S
Topivert - TopiVert developing topical anti-inflammatories for the treatment of diseases of the gastrointestinal tract and eye. About Topivert - Health/Medical company in United Kingdom | …See details»
Topivert Pharma Ltd. - Drug pipelines, Patents, Clinical trials
Explore Topivert Pharma Ltd. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»
TopiVert | Biotechnology - The Pharmaletter
TopiVert A private, clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The company's …See details»
TOP-1890 - Drug Targets, Indications, Patents - Synapse - Patsnap
TOP-1890, Initially developed by Topivert Pharma Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Digestive System Disorders, Active Indication: Colitis, …See details»
TOP-1257 - Drug Targets, Indications, Patents - Synapse - Patsnap
Non-systemic kinase inhibitors (NSKI) offer a novel approach for the treatment of Diabetic Macular EdemaSee details»
TOP 1630 - AdisInsight
14 May 2019 Topivert Pharma completes the phase II/III THEIA-1 trial in Dry eyes in USA (NCT03833388) You need to be a logged in or subscribed to view this content Request demo. …See details»
TOP 1288 - AdisInsight - Springer
Originator TopiVert Class Anti-inflammatories; Small molecules Mechanism of Action Protein kinase inhibitors Orphan Drug Status Orphan designation is assigned by a regulatory body to …See details»
SARL TOPIVERT Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SARL TOPIVERT of TIZI OUZOU, Wilaya de Tizi Ouzou. Get the latest business insights from Dun & …See details»
TOP-1106 - Drug Targets, Indications, Patents - Synapse - Patsnap
TOP-1106: a SRC inhibitors, p38α inhibitors Drug, Initially developed by Topivert Pharma Ltd., Now, its global highest R&D status is Preclinical, Mechanism: SRC inhibitors,p38α …See details»